Summary
- Profile Type
- Technology offer
- POD Reference
- TOHR20240228022
- Term of Validity
- 28 February 2024 - 27 February 2025
- Company's Country
- Croatia
- Type of partnership
- Commercial agreement with technical assistanceResearch and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Croatian academic research group active in the field of high-throughput monoclonal antibodies (mAb) development for cutting-edge applications, including proteome analysis offers its collection of mAb. Additionally, the offer includes customized production of proteins. The potential application field is industry and academia worldwide, for research and experimental therapies. The center is interested in non-exclusive licensing agreements or service agreement and joint research.
- Full Description
-
This higher education institution was established in Croatia in 1955. The research centre offering the technology was established in 2006, as a part of the higher education institution with focus on high-throughput monoclonal antibodies (mAb) development for cutting-edge applications, including proteome analysis. Its expertise lies in the field of in vivo immunology, regulation of innate and adaptive immunity and pathogenesis of murine cytomegalovirus (MCMV). It also
disposes of several hundred hybridoma cell lines secreting mAbs to a large variety of target proteins. The research centre is offering a database of mAbs, a collection covering proteins of Varicella-Zoster Virus (VZV), mouse cytomegalovirus (MCMV), human cytomegalovirus (HCMV) and human (mostly) and mouse lymphocytes receptors and their ligands.
The database is a collection of monoclonal antibodies (mAbs). For most of the targeted proteins, there is no other antibody available.
In addition, the offer includes customized production of proteins, monoclonal antibodies and hybridoma cell lines:
1. Expression of proteins of interest as an essential component of the monoclonal antibody (mAb) development process.
2. Multiple immunizations of Balb/c mice or specified mouse strain(s).
3. Generation of custom hybridoma cell lines stably secreting mouse mAbs specific to your target protein.
4. Large scale production of antibodies: in vitro bioreactor mAb production and purification. Antibodies' testing by different techniques.
The research centre is interested in collaborating with:
• an industry partner interested in non-exclusive licensing agreements or services agreement, preferably with an expertise in sales of biological materials
• academic institutions interested in joint fundamental research, development of research tools and reagents, innovative diagnostic and therapeutic products, with expertise in the area of immunology and virology research.
The reason for cooperation is international expansion. - Advantages and Innovations
-
The database represents a collection of monoclonal antibodies (mAbs). For most of the targeted proteins, there is no other antibody available.
The research group continuously generates mAbs of the highest quality, which have been demanded by industrial and academic users worldwide due to their great significance in the studies of pathogenesis of viral disease. Their potential applications are also in translational research, including the characterization of diagnostic markers and experimental therapies.
Since its establishment the research group has participated in more than thirty collaborative projects with prestigious research institutes, universities and biotech SMEs from SE Europe, EU and the USA. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
The client is looking for:
- an industry partner interested in non-exclusive licensing agreements or service agreement
(preferably with expertise in sales of biological materials)
- an academic institutions with expertise in the area of immunology and virology research for :
• joint fundamental research,
• development of research tools and reagents,
• innovative diagnostic and therapeutic products. - Type and Size of Partner
- SME 50 - 249Big companyR&D InstitutionSME <=10SME 11-49OtherUniversity
- Type of partnership
- Commercial agreement with technical assistanceResearch and development cooperation agreement
Call details
- Coordinator required
-
Yes
Dissemination
- Technology keywords
- 06001012 - Medical Research06001013 - Medical Technology / Biomedical Engineering06001018 - Virus, Virology/Antibiotics/Bacteriology06001006 - Human vaccines
- Market keywords
- 05007007 - Other medical/health related (not elsewhere classified)
- Targeted countries
- All countries